Abstract
Extranodal extension (ENE) is a prognostic indicator of aggressiveness for papillary thyroid cancer (PTC). The association between the size of metastatic nodes and the prevalence of ENE has not been previously explored. However, there is a common belief that small lymph nodes with metastatic disease do not significantly impact patient outcome. This study investigates the relationship between the prevalence of ENE and the size of a positive lymph node. Linear dimensions and malignant histological characteristics of 979 metastatic lymph nodes from 152 thyroid cancer patients were retrospectively analyzed. Data was analyzed using chi-square tests and multilevel logistic regression modeling. ENE was present in 144 of 979 lymph nodes; the sizes of the involved lymph nodes ranged from 0.9 to 44 mm. ENE was identified in 7.8% of lymph nodes measuring ≤ 5 mm, 18.9% between 6 and 10 mm, 23.1% between 11 and 15 mm, 25.0% between 16 and 20 mm, and 14.0% between 21 and 25 mm in size. The association between node size and ENE status was significant (odds ratio (OR) = 1.07, confidence interval (CI) = [1.04, 1.11]). The size of the metastatic focus directly correlated with ENE (OR = 1.07, 95% CI = [1.07, 1.14], p value < 0.001). Increasing lymph node size increases the likelihood of ENE for metastatic PTC. Importantly, small positive lymph nodes can also harbor ENE to a significant extent. Further studies are required to determine the clinical and prognostic significance of lymph node size and the presence of ENE.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26: 1–133, 2016.
Scherl S, Mehra S, Clain J et al. The effect of surgeon experience on the detection of metastatic lymph nodes in the central compartment and the pathologic features of clinically unapparent metastatic lymph nodes: what are we missing when we don't perform a prophylactic dissection of central compartment lymph nodes in papillary thyroid cancer? Thyroid 24: 1282–1288, 2014.
Randolph GW, Duh QY, Heller KS et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22: 1144–1152, 2012.
Ito Y, Tomoda C, Uruno T et al. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg 30: 91–99, 2006.
Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135: 139–148, 2004.
Leboulleux S, Rubino C, Baudin E et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90: 5723–5729, 2005.
Ito Y, Hirokawa M, Jikuzono T et al. Extranodal tumor extension to adjacent organs predicts a worse cause-specific survival in patients with papillary thyroid carcinoma. World J Surg 31: 1194–1201, 2007.
Lango M, Flieder D, Arrangoiz R et al. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. Thyroid 23: 1099–1105, 2013.
Yamashita H, Noguchi S, Murakami N, Kawamoto H, Watanabe S Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. Cancer 80: 2268–2272, 1997.
World Medical A World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310: 2191–2194, 2013.
Du E, Wenig BM, Su HK et al. Inter-observer variation in the pathologic identification of extranodal extension in nodal metastasis from papillary thyroid carcinoma. Thyroid 26: 816–819, 2016.
Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery 148: 1100–1106; discussion 1006-1107, 2010.
Wada N, Duh QY, Sugino K et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 237: 399–407, 2003.
Urken ML, Haser GC, Likhterov I, Wenig BM The impact of metastatic lymph nodes on risk stratification in differentiated thyroid cancer: have we reached a higher level of understanding? Thyroid 26: 481–488, 2016.
Vassilopoulou-Sellin R, Schultz PN, Haynie TP Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 78: 493–501, 1996.
Funding
We would like to acknowledge the generous support of the THANC Foundation and the Mount Sinai Health System.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Dr. Urken is the Medical Advisor of the THANC Foundation.
Rights and permissions
About this article
Cite this article
Rowe, M.E., Ozbek, U., Machado, R.A. et al. The Prevalence of Extranodal Extension in Papillary Thyroid Cancer Based on the Size of the Metastatic Node: Adverse Histologic Features Are Not Limited to Larger Lymph Nodes. Endocr Pathol 29, 80–85 (2018). https://doi.org/10.1007/s12022-018-9518-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12022-018-9518-7